these LRRK2 risk variants share substantial similarities with patients with sporadic PD. It has been suggested that the G2385R variant is associated with a lower age at onset (AAO) of PD.
3 However, it is unknown whether the presence of multiple LRRK2 risk variants modulates the AAO of PD. We hypothesize that increases in the genetic burden of LRRK2 risk variants may be associated with a younger AAO. To test this hypothesis, we conducted a correlation study among a cohort of participants with PD who carried the LRRK2 risk variants S1647T, R1628P, and G2385R.
Methods | A total of 1284 patients with PD were assessed at the movement disorder outpatient clinics at the National Neuroscience Institute. The clinical diagnosis was based on the UK PD Brain Bank criteria. 4 Our study was approved by the SingHealth Centralised institutional review board. Written informed consent was obtained from all of the participants. Clinical data collected included age, AAO, race/ethnicity, sex, and family history of PD. The LRRK2 variants S1647T, R1628P, and G2385R were genotyped by TaqMan (Thermo Fisher Scientific) real-time polymerase chain reaction. Ten percent of the results (n = 129) were selected for Sanger sequencing to check for errors. The concordance rate of the 2 genotyping methods in this study was 100%. The AAO of carriers and noncarriers of LRRK2 variant(s) was compared using a 2-sample t test and a Wilcoxon rank sum test, and statistical significance was set at P<.05.
Results | Among the patients with PD, the mean (SD) AAO was 62.3 (10.8) years, with women (63.3 [10.3] years) developing PD later than men (61.6 [11.2] years) (95% CI, 0.49-2.90; P = .006). A total of 495 participants had no S1647T, R1628P, or G2385R variant, while 789 participants carried at least 1 of these risk variants. Because all 92 R1628P and all 84 G2385R carriers also had S1647T, the group of patients who carried a single variant was the same group who carried the S1647T variant but neither of the other 2 variants. The mean (SD) AAO of participants with no risk variants was 62.5 (10.5) years. By comparison, with 1 risk variant, the mean (SD) AAO was 62.3 (10.9) years (95% CI, −1.35 to 1.18; P = .90), while with 2 variants (R1628P + S1647T or G2385R + S1647T) the mean (SD) AAO was 61.3 (11.2) years (95% CI, −0.70 to 3.15; P = .21) and with all 3 variants (S1647T, R1628P, and G2385R) the mean (SD) AAO was 52.6 (12.3) years (95% CI, 3.29-16.51; P = .004) ( Figure) . The difference in the AAO between the carriers with all 3 variants and the noncarriers remained significant after adjusting the significance level for multiple testing using the Bonferroni correction to P < .05 / 3 = .02. A Wilcoxon test comparing participants who carried 3 risk alleles vs noncarriers yielded P = .02, which was also significant at the Bonferronicorrected level of 0.02. Among the 10 participants who carried all 3 variants, 4 (40%) developed PD before age 50 years, while only 51 participants (10.3%) in 495 noncarriers reported their first PD-related complaint before 50 years. A further analysis conducted among an independent Asian cohort 5 of 465 patients from
Malaysia was used to substantiate our results. We identified 4 patients who had all 3 risk alleles in the Malaysian cohort. The AAO values for these 4 participants were 45, 49, 57, and 59 years, respectively, with a mean (SD) AAO of 52.5 (5.7) years, which was lower than the 60.1 (11.0) for noncarriers. The 7.6-year difference was comparable with the 8.7 years in our cohort, although the P values from a 2-sample t test (P = .10) and a Wilcoxon rank sum test (95% CI, −3.24 to 18.35; P = .11) were of borderline significance because of the smaller sample size.
Discussion | In this study, we examined the association of LRRK2 risk variants with the AAO of PD. Our data show that the presence of multiple risk variants in a patient with PD may significantly lower the AAO of PD. These LRRK2 variants are located in the genetic coding regions and may potentially alter protein function. The R1628P and S1647T variants are located in the C terminal of Ras of complex proteins domain, whereas the G2385R variant is located in the WD40 domain. 6 Thus, these coding variants may contribute to PD development through distinct mechanisms and additively lower the AAO of PD. Our data suggest that increases in the genetic burden of LRRK2 variants may be associated with an earlier AAO in PD. Mean ages (95% CIs) shown in participants with PD carrying specified numbers of LRRK2 risk variant. To the Editor In their recent article, Zhang et al 1 assessed the therapeutic potential of the proteasome inhibitor bortezomib in 5 patients with neuromyelitis optica spectrum disorder (NMOSD) who had responded poorly to conventional immunosuppression. Bortezomib treatment resulted in disease remission for 1 year and was associated with a decline in antiaquaporin-4 antibody titers. Bortezomib is used for treating autoimmune diseases based on its ability to deplete plasma cells, owing to their extremely high amount of protein biosynthesis. However, studies in lupus mice and systemic lupus erythematosus have demonstrated that when bortezomib is discontinued, the plasma cells quickly regenerate due to the activation of autoreactive B cells. 2, 3 In line with this, bortezomib treatment led to an immediate decrease in antidouble-stranded DNA antibody levels that rose again after a short-term treatment. 4 Therefore, bortezomib has been suggested for use as an induction or combination therapy with the targeting of plasma cell precursors by B cell-depleting therapy to produce long-lasting effects in autoimmune diseases. 2,4 These data have raised concerns regarding the long-term effects of bortezomib and the treatment strategies that are available after 4 courses of treatment for NMOSD. In this study, 4 patients (80%) maintained a relapse-free status for more than 9 months following the last bortezomib cycle with just an oral corticosteroid treatment. The counts of peripheral white blood B cells and plasma cells remained low even after 1 year of treatment. However, because cell counts were measured only before and 1 year after bortezomib treatment, we do not understand how the serial B cell and plasma cell counts changed over the year. Moreover, it is not clear if the remission period (longer than 9 months) seen in this study is a disease-specific response and how long it would continue. The benefits of bortezomib must be weighed against its adverse effects. In this study, before treatment with bortezomib, 2 patients had been treated with only azathioprine, which has a lower efficacy in terms of disease stabilization compared with rituximab.
5 Although bortezomib was found to be safe in this study, considering its potential adverse effects, which include infection, cytopenia, and polyneuropathy, and the small sample size, it should be used with caution in patients with NMOSD, because rituximab might have a lower risk of producing adverse effects than bortezomib. For patients with highly recurrent NMOSD who are unresponsive to conventional immunosuppressive treatments, bortezomib may serve as a salvage therapy. However, additional studies are required to validate its benefits.
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